View ValuationVimian Group 향후 성장Future 기준 점검 4/6Vimian Group (는) 각각 연간 26.1% 및 9.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 24.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 8.8% 로 예상됩니다.핵심 정보26.1%이익 성장률24.25%EPS 성장률Medical Equipment 이익 성장13.4%매출 성장률9.5%향후 자기자본이익률8.78%애널리스트 커버리지Low마지막 업데이트07 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • Jul 01Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at €2.58. The fair value is estimated to be €3.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 22% in 2 years. Earnings are forecast to grow by 83% in the next 2 years.공시 • Apr 29Vimian Group AB (publ) to Report Fiscal Year 2026 Results on Feb 11, 2027Vimian Group AB (publ) announced that they will report fiscal year 2026 results on Feb 11, 2027Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Magnus Welander was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Dec 24Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family.Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family on December 23, 2025. The acquisition is financed with available funds. Following the acquisition, I-Vet will be integrated into Vimian’s Diagnostics segment, and CEO Daniele Franzini will continue to lead I-Vet as part of Vimian. For the period ending December 31, 2024, I-Vet S.R.L. reported total revenue of €5.6 million and has 75 team members. The acquisition is expected to be completed on or around March 2, 2026. The acquisition is expected to have marginal impact on earnings per share in the 2026 financial year.공시 • Nov 24+ 1 more updateVimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appointed Alireza Tajbakhsh as Chief Executive Officer, effective 24 November 2025. Alireza Tajbakhsh joined Vimian in 2021 and is currently Head of the Veterinary Services segment and interim Head of the MedTech segment in Vimian. Alireza Tajbakhsh (42) brings extensive international leadership experience from fast-growing entrepreneurial companies in the media and life science sectors. Since joining Vimian in 2021, he has successfully led the Veterinary Services segment and served as a member of the group management team. Since July 2025, he has also held the interim position as Head of Vimian’s MedTech segment, delivering strong early progress and results. Prior to joining Vimian, Alireza held senior management positions at Omnicom Media Group and Modern Times Group (MTG). Alireza holds an M.Sc. in Business and Administration from the Stockholm School of Economics. The board thank Carl-Johan Zetterberg Boudrie for capably serving as interim CEO in addition to his role as CFO over the past months. Carl-Johan Zetterberg will continue as a strong partner to Ali in his position as CFO. Alireza Tajbakhsh will, in addition to the role as Group CEO, continue to hold the interim operational responsibility for Vimian's MedTech segment, while the recruitment for a permanent Head of MedTech is ongoing.공시 • Oct 20Vimian Group AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Vimian Group AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026공시 • Sep 23Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026.공시 • Sep 16+ 2 more updatesVimian Group AB (publ) to Report Q1, 2026 Results on Apr 29, 2026Vimian Group AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026공시 • Jul 18+ 1 more updateVimian Group AB Announces Executive Management Changes, Effective 17 July 2025Vimian Group AB announced that effective today, Alireza Tajbakhsh will, in addition to his current role as Head of Vimian’s Veterinary Services segment, assume interim operational responsibility for Vimian’s MedTech segment. He succeeds Guy Spörri, who has decided to leave the company at year-end. Furthermore, Bart Bremer, Chief People Officer, is appointed as a member of Vimian’s executive management team.공시 • Jun 13Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc.Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc. on June 13, 2025. AllAccem Inc. had revenues of around $9 million for the twelve months ending April 2025, and an EBITDA margin significantly above the Vimian Group average. AllAccem will become part of Vimian’s MedTech segment and Jeffery Whiteford, founder and CEO of AllAccem Inc., will continue to lead the integrated business. The acquisition is expected to have marginal impact on earnings per share in the current financial year. The acquisition of AllAccem Inc. is expected to be completed on or around 13 June and is financed with available funds.공시 • Apr 30Vimian Group AB (publ) Elects Pia Marions as Board MemberVimian Group AB (publ) at its Annual General Meeting held on 29 April 2025, Pia Marions was newly elected, as Board members for the time until the end of the next Annual General Meeting.공시 • Mar 14Vimian Group AB (publ) to Report Q4, 2025 Results on Feb 12, 2026Vimian Group AB (publ) announced that they will report Q4, 2025 results on Feb 12, 2026공시 • Dec 04+ 3 more updatesVimian Group AB (publ) to Report Q2, 2025 Results on Jul 18, 2025Vimian Group AB (publ) announced that they will report Q2, 2025 results on Jul 18, 2025Buy Or Sell Opportunity • Nov 07Now 21% undervaluedOver the last 90 days, the stock has risen 30% to €3.74. The fair value is estimated to be €4.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 28,005% in the next 2 years.Reported Earnings • Oct 24Third quarter 2024 earnings released: €0.004 loss per share (vs €0.016 profit in 3Q 2023)Third quarter 2024 results: €0.004 loss per share (down from €0.016 profit in 3Q 2023). Revenue: €87.6m (up 9.6% from 3Q 2023). Net loss: €2.13m (down 129% from profit in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.공시 • Oct 12Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025.New Risk • Aug 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (14% increase in shares outstanding).Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: €0.01 (vs €0.007 in 2Q 2023)Second quarter 2024 results: EPS: €0.01 (up from €0.007 in 2Q 2023). Revenue: €91.1m (up 12% from 2Q 2023). Net income: €4.87m (up 63% from 2Q 2023). Profit margin: 5.3% (up from 3.7% in 2Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.Recent Insider Transactions • Jul 19Chief Executive Officer of Nextmune recently sold €309k worth of stockOn the 15th of July, Magnus Kjellberg sold around 100k shares on-market at roughly €3.09 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €20m more than they sold in the last 12 months.Recent Insider Transactions • Jun 26Director recently bought €931k worth of stockOn the 19th of June, Gabriel Fitzgerald bought around 316k shares on-market at roughly €2.95 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €21m more in shares than they have sold in the last 12 months.공시 • May 23Vimian Group AB (publ) Elects Magnus Welander to Board as Chairman of the BoardVimian Group AB (publ) at its Annual General Meeting held on 22 May 2024 announced that Magnus Welander was newly elected, as Board members for the time until the end of the next Annual General Meeting. Magnus Welander was elected as chairman of the Board.New Risk • May 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (14% increase in shares outstanding).Reported Earnings • May 02First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.008. Revenue: €92.2m (up 4.7% from 1Q 2023). Net income: €3.50m (down 35% from 1Q 2023). Profit margin: 3.8% (down from 6.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany.Reported Earnings • Apr 12Full year 2023 earnings released: EPS: €0.022 (vs €0.017 loss in FY 2022)Full year 2023 results: EPS: €0.022 (up from €0.017 loss in FY 2022). Revenue: €331.7m (up 18% from FY 2022). Net income: €9.84m (up €16.6m from FY 2022). Profit margin: 3.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany.공시 • Apr 05Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion.Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,302,624 Price\Range: SEK 25 Transaction Features: Regulation S; Rights OfferingReported Earnings • Feb 16Full year 2023 earnings released: EPS: €0.022 (vs €0.017 loss in FY 2022)Full year 2023 results: EPS: €0.022 (up from €0.017 loss in FY 2022). Revenue: €331.8m (up 18% from FY 2022). Net income: €9.84m (up €16.6m from FY 2022). Profit margin: 3.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany.Buy Or Sell Opportunity • Feb 07Now 24% undervaluedOver the last 90 days, the stock has risen 19% to €2.43. The fair value is estimated to be €3.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Meanwhile, the company became loss making.공시 • Dec 22Vimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare. Patrik Eriksson (56) has vast international experience from 25 years as general manager in the global medtech and life science industries. Since 2020, he is President of the dental company Nobel Biocare, part of Envista. Prior to that, he worked seven years at the global life sciences group Danaher (NYSE:DHR) as President of two of its medtech companies, KavoKerr and Ormco. He has led international organizations with more than 6,500 employees and revenues of USD 1.5 billion. He is a Swedish citizen and holds a M.Sc. in Business and Administration from the Stockholm School of Economics. Patrik Eriksson succeeds Fredrik Ullman whose departure at year-end was announced on 29 June 2023.Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: €0.016 (vs €0.004 loss in 3Q 2022)Third quarter 2023 results: EPS: €0.016 (up from €0.004 loss in 3Q 2022). Revenue: €80.2m (up 13% from 3Q 2022). Net income: €7.43m (up €9.05m from 3Q 2022). Profit margin: 9.3% (up from net loss in 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.공시 • Sep 26Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million.Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million on September 21, 2023. Fidelio Capital completed the acquisition of a 12% stake in Vimian Group AB (publ) on September 21, 2023.Recent Insider Transactions • Sep 24Chairman of the board recently bought €20m worth of stockOn the 21st of September, Gabriel Fitzgerald bought around 10m shares on-market at roughly €1.97 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gabriel has been a buyer over the last 12 months, purchasing a net total of €20m worth in shares.공시 • Sep 13+ 5 more updatesVimian Group AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vimian Group AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024Reported Earnings • Aug 18Second quarter 2023 earnings released: EPS: €0.007 (vs €0.026 in 2Q 2022)Second quarter 2023 results: EPS: €0.007 (down from €0.026 in 2Q 2022). Revenue: €81.3m (up 21% from 2Q 2022). Net income: €2.99m (down 70% from 2Q 2022). Profit margin: 3.7% (down from 15% in 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.공시 • Jun 30Vimian Group AB (publ) Announces Fredrik Ullman Step Down as CEOVimian Group AB (publ) announced that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end. The recruitment process for a new CEO will be initiated immediately and Fredrik Ullman will remain as CEO in the interim.공시 • Jun 03Vimian Group AB (Publ) Elects Robert Belkic as New Board MemberVimian Group AB (publ) at the Annual General Meeting 2 June 2023, announced Robert Belkic was newly elected, as Board members for the time until the end of the next Annual General Meeting.Reported Earnings • May 05Full year 2022 earnings released: €0.017 loss per share (vs €0.019 profit in FY 2021)Full year 2022 results: €0.017 loss per share (down from €0.019 profit in FY 2021). Revenue: €281.3m (up 62% from FY 2021). Net loss: €6.74m (down 202% from profit in FY 2021).Recent Insider Transactions • Mar 13Chief Executive Officer recently bought €94k worth of stockOn the 9th of March, Fredrik Ullman bought around 40k shares on-market at roughly €2.36 per share. This transaction amounted to 2.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Fredrik's only on-market trade for the last 12 months.Reported Earnings • Mar 09Full year 2022 earnings released: €0.017 loss per share (vs €0.019 profit in FY 2021)Full year 2022 results: €0.017 loss per share (down from €0.019 profit in FY 2021). Revenue: €287.8m (up 66% from FY 2021). Net loss: €6.74m (down 202% from profit in FY 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €2.01, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total loss to shareholders of 55% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.67 per share.Buying Opportunity • Feb 28Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €2.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings is also forecast to grow by 43% per annum over the same time period.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to €2.79, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Total loss to shareholders of 59% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.82 per share.Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to €2.66, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €3.02 per share.Reported Earnings • Nov 17Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €72.4m (up 75% from 3Q 2021). Net loss: €1.62m (loss widened 488% from 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.공시 • Nov 17+ 3 more updatesVimian Group AB (publ) to Report Q2, 2023 Results on Aug 17, 2023Vimian Group AB (publ) announced that they will report Q2, 2023 results on Aug 17, 2023Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Director Theodor Bonnier is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Valuation Update With 7 Day Price Move • Oct 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to €3.00, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 67% over the past year.공시 • Oct 25Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023.Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €2.75, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 70% over the past year.공시 • Sep 09Vimian Appoints Carl-Johan Ehn as General Counsel and Member of the Vimian Group Management TeamVimian appointed Carl-Johan Ehn as General Counsel and member of the Vimian Group management team as of 7 September 2022. Carl-Johan Ehn has over two decades of experience from international law in the global pharmaceutical industry at Zoetis and Pfizer, as well as from Mannheimer Swartling law firm. He joins Vimian from animal health company Zoetis where he held various leading positions over the past nine years, most recently as Chief Counsel for its international operations. The General Counsel is a new addition to the Vimian Group management team and will focus on supporting the company in the execution of commercial strategies, and ensuring high corporate governance and compliance standards. Carl-Johan Ehn joined Vimian on 15 August and was appointed member of the Vimian Group management team on 7 September.Valuation Update With 7 Day Price Move • Sep 03Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €3.01, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 70% over the past year.Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €68.6m (up 74% from 2Q 2021). Net income: €9.99m (up €13.1m from 2Q 2021). Profit margin: 15% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 32%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany.공시 • Aug 03Vimian Group AB (publ) (OM:VIMIAN) acquired Heiland Gmbh.Vimian Group AB (publ) (OM:VIMIAN) acquired Heiland Gmbh on August 1, 2022. Heiland a family-owned business that has annual revenues of around €1.5 million. Vimian Group AB (publ) (OM:VIMIAN) completed the acquisition of Heiland Gmbh on August 1, 2022.공시 • Jul 15Vimian Group AB (publ) Appoints Carl-Johan Zetterberg Boudrie as CFO and Member of Management TeamVimian Group appoints Carl-Johan Zetterberg Boudrie as new Chief Financial Officer and intends to continue to build out its finance organisation to support Vimian's growth journey. Carl-Johan assumes the position as CFO and member of the Vimian Group management team, and succeeds Henrik Halvorsen who has decided to focus on his role as CFO of Vimian's Specialty Pharma segment Nextmune. Carl-Johan Zetterberg Boudrie has extensive experience as CFO in publicly traded companies as well as from senior leadership positions within business development, M&A and management consulting at Beijer Electronics, SEB and Capgemini. The past six years, Carl-Johan held positions as CFO and subsequently CEO of the technology company Doro AB (publ) listed on Nasdaq Stockholm. Most recently, he was CEO of Careium AB (publ), a spin-off from Doro AB. Carl-Johan Zetterberg Boudrie succeeds Henrik Halvorsen who has held dual positions as CFO of Vimian and CFO of Vimian's Specialty Pharma segment Nextmune, and who now decided to focus solely on his position at Nextmune. Henrik Halvorsen will remain as Vimian's CFO until Carl-Johan Zetterberg Boudrie has assumed his position. Carl-Johan will assume the position as CFO of Vimian as soon as a successor has been appointed for his current position.Buying Opportunity • Jun 16Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €6.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last year. Meanwhile, the company has become profitable. Revenue is forecast to grow by 73% in 2 years. Earnings is forecast to grow by 1,371% in the next 2 years.Reported Earnings • May 06Full year 2021 earnings released: EPS: €0.019 (vs €0.18 in FY 2020)Full year 2021 results: EPS: €0.019 (down from €0.18 in FY 2020). Revenue: €173.4m (up 143% from FY 2020). Net income: €6.59m (down 88% from FY 2020). Profit margin: 3.8% (down from 74% in FY 2020). Over the next year, revenue is forecast to grow 51%, compared to a 11% growth forecast for the industry in Germany.공시 • May 06+ 3 more updatesVimian Group AB (publ) to Report Q2, 2022 Results on Aug 11, 2022Vimian Group AB (publ) announced that they will report Q2, 2022 results on Aug 11, 2022Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theodor Bonnier is the most experienced director on the board, commencing their role in 2021. Independent Director Mikael Dolsten was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Apr 05Vimian Group AB (publ) (OM : VIMIAN) acquired VerticalVet, LLC.Vimian Group AB (publ) (OM : VIMIAN) acquired VerticalVet, LLC on April 1, 2022. Vimian Group AB (publ) (OM : VIMIAN) completed the acquisition of VerticalVet, LLC on April 1, 2022.Reported Earnings • Mar 11Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: €0.017 (down from €0.18 in FY 2020). Revenue: €178.2m (up 150% from FY 2020). Net income: €6.59m (down 88% from FY 2020). Profit margin: 3.7% (down from 74% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 36%, compared to a 11% growth forecast for the industry in Germany.공시 • Feb 04Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire Kahu Vet Group for €22.5 million.Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire Kahu Vet Group for €22.5 million on February 3, 2022. The consideration consists of upfront payment of €12.1 million and potential earnout of €10.4 million subject to financial performance over three years. The consideration of €12.1 million id financed with available funds. For the year 2021, Kahu Vet Group reported revenue of approximately €8.5 million and EBITDA of approximately €1.6 million. The transaction is expected to close on or around March 1, 2022. Selling management has committed to reinvest part of the proceeds in Vimian shares.Reported Earnings • Dec 01Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2021 results: €0.001 loss per share. Revenue: €41.5m (flat on 3Q 2020). Net loss: €275.0k (flat on 3Q 2020). Revenue exceeded analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 35%, compared to a 13% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Nov 27Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to €7.50, the stock trades at a forward P/E ratio of 85x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €5.28 per share.Valuation Update With 7 Day Price Move • Nov 27Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to €7.50, the stock trades at a forward P/E ratio of 85x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €5.28 per share.이익 및 매출 성장 예측DB:0V0 - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20285637678112512/31/2027517646496512/31/202647147428053/31/20264343793112N/A12/31/20254253191106N/A9/30/2025421326075N/A6/30/2025404236680N/A3/31/2025391195164N/A12/31/2024375194458N/A9/30/202435203651N/A6/30/2024345103146N/A3/31/20243358-34-18N/A12/31/202333210-43-29N/A9/30/2023325-5-36-25N/A6/30/2023316-14-53-42N/A3/31/2023301-7515N/A12/31/2022281-71525N/A9/30/202225516-63N/A6/30/202222517314N/A3/31/20221984518N/A12/31/20211737516N/A9/30/202115358919N/A6/30/202113258717N/A3/31/202110460614N/A12/31/20207153-15N/A12/31/201925-1N/A2N/A12/31/20188-1N/A-2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 0V0 의 연간 예상 수익 증가율(26.1%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: 0V0 의 연간 수익(26.1%)이 German 시장(16.9%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 0V0 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 0V0 의 수익(연간 9.5%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 0V0 의 수익(연간 9.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 0V0의 자본 수익률은 3년 후 8.8%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/07 07:22종가2026/07/07 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vimian Group AB (publ)는 10명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierJonathon UnwinBarclaysKristofer Liljeberg-SvenssonCarnegie Investment Bank AB7명의 분석가 더 보기
Buy Or Sell Opportunity • Jul 01Now 20% undervaluedThe stock has been flat over the last 90 days, currently trading at €2.58. The fair value is estimated to be €3.24, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 22% in 2 years. Earnings are forecast to grow by 83% in the next 2 years.
공시 • Apr 29Vimian Group AB (publ) to Report Fiscal Year 2026 Results on Feb 11, 2027Vimian Group AB (publ) announced that they will report fiscal year 2026 results on Feb 11, 2027
Board Change • Dec 30Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Magnus Welander was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Dec 24Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family.Vimian Group AB (publ) (OM:VIMIAN) entered into an agreement to acquire I-Vet S.R.L. from the Franzini family on December 23, 2025. The acquisition is financed with available funds. Following the acquisition, I-Vet will be integrated into Vimian’s Diagnostics segment, and CEO Daniele Franzini will continue to lead I-Vet as part of Vimian. For the period ending December 31, 2024, I-Vet S.R.L. reported total revenue of €5.6 million and has 75 team members. The acquisition is expected to be completed on or around March 2, 2026. The acquisition is expected to have marginal impact on earnings per share in the 2026 financial year.
공시 • Nov 24+ 1 more updateVimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appointed Alireza Tajbakhsh as Chief Executive Officer, effective 24 November 2025. Alireza Tajbakhsh joined Vimian in 2021 and is currently Head of the Veterinary Services segment and interim Head of the MedTech segment in Vimian. Alireza Tajbakhsh (42) brings extensive international leadership experience from fast-growing entrepreneurial companies in the media and life science sectors. Since joining Vimian in 2021, he has successfully led the Veterinary Services segment and served as a member of the group management team. Since July 2025, he has also held the interim position as Head of Vimian’s MedTech segment, delivering strong early progress and results. Prior to joining Vimian, Alireza held senior management positions at Omnicom Media Group and Modern Times Group (MTG). Alireza holds an M.Sc. in Business and Administration from the Stockholm School of Economics. The board thank Carl-Johan Zetterberg Boudrie for capably serving as interim CEO in addition to his role as CFO over the past months. Carl-Johan Zetterberg will continue as a strong partner to Ali in his position as CFO. Alireza Tajbakhsh will, in addition to the role as Group CEO, continue to hold the interim operational responsibility for Vimian's MedTech segment, while the recruitment for a permanent Head of MedTech is ongoing.
공시 • Oct 20Vimian Group AB (publ) to Report Fiscal Year 2025 Final Results on Mar 19, 2026Vimian Group AB (publ) announced that they will report fiscal year 2025 final results on Mar 19, 2026
공시 • Sep 23Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026Vimian Group AB (publ), Annual General Meeting, Apr 29, 2026.
공시 • Sep 16+ 2 more updatesVimian Group AB (publ) to Report Q1, 2026 Results on Apr 29, 2026Vimian Group AB (publ) announced that they will report Q1, 2026 results on Apr 29, 2026
공시 • Jul 18+ 1 more updateVimian Group AB Announces Executive Management Changes, Effective 17 July 2025Vimian Group AB announced that effective today, Alireza Tajbakhsh will, in addition to his current role as Head of Vimian’s Veterinary Services segment, assume interim operational responsibility for Vimian’s MedTech segment. He succeeds Guy Spörri, who has decided to leave the company at year-end. Furthermore, Bart Bremer, Chief People Officer, is appointed as a member of Vimian’s executive management team.
공시 • Jun 13Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc.Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire AllAccem Inc. on June 13, 2025. AllAccem Inc. had revenues of around $9 million for the twelve months ending April 2025, and an EBITDA margin significantly above the Vimian Group average. AllAccem will become part of Vimian’s MedTech segment and Jeffery Whiteford, founder and CEO of AllAccem Inc., will continue to lead the integrated business. The acquisition is expected to have marginal impact on earnings per share in the current financial year. The acquisition of AllAccem Inc. is expected to be completed on or around 13 June and is financed with available funds.
공시 • Apr 30Vimian Group AB (publ) Elects Pia Marions as Board MemberVimian Group AB (publ) at its Annual General Meeting held on 29 April 2025, Pia Marions was newly elected, as Board members for the time until the end of the next Annual General Meeting.
공시 • Mar 14Vimian Group AB (publ) to Report Q4, 2025 Results on Feb 12, 2026Vimian Group AB (publ) announced that they will report Q4, 2025 results on Feb 12, 2026
공시 • Dec 04+ 3 more updatesVimian Group AB (publ) to Report Q2, 2025 Results on Jul 18, 2025Vimian Group AB (publ) announced that they will report Q2, 2025 results on Jul 18, 2025
Buy Or Sell Opportunity • Nov 07Now 21% undervaluedOver the last 90 days, the stock has risen 30% to €3.74. The fair value is estimated to be €4.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 28,005% in the next 2 years.
Reported Earnings • Oct 24Third quarter 2024 earnings released: €0.004 loss per share (vs €0.016 profit in 3Q 2023)Third quarter 2024 results: €0.004 loss per share (down from €0.016 profit in 3Q 2023). Revenue: €87.6m (up 9.6% from 3Q 2023). Net loss: €2.13m (down 129% from profit in 3Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.
공시 • Oct 12Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025Vimian Group AB (publ), Annual General Meeting, Apr 29, 2025.
New Risk • Aug 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (14% increase in shares outstanding).
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: €0.01 (vs €0.007 in 2Q 2023)Second quarter 2024 results: EPS: €0.01 (up from €0.007 in 2Q 2023). Revenue: €91.1m (up 12% from 2Q 2023). Net income: €4.87m (up 63% from 2Q 2023). Profit margin: 5.3% (up from 3.7% in 2Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Jul 19Chief Executive Officer of Nextmune recently sold €309k worth of stockOn the 15th of July, Magnus Kjellberg sold around 100k shares on-market at roughly €3.09 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought €20m more than they sold in the last 12 months.
Recent Insider Transactions • Jun 26Director recently bought €931k worth of stockOn the 19th of June, Gabriel Fitzgerald bought around 316k shares on-market at roughly €2.95 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €21m more in shares than they have sold in the last 12 months.
공시 • May 23Vimian Group AB (publ) Elects Magnus Welander to Board as Chairman of the BoardVimian Group AB (publ) at its Annual General Meeting held on 22 May 2024 announced that Magnus Welander was newly elected, as Board members for the time until the end of the next Annual General Meeting. Magnus Welander was elected as chairman of the Board.
New Risk • May 16New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (14% increase in shares outstanding).
Reported Earnings • May 02First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: €0.008. Revenue: €92.2m (up 4.7% from 1Q 2023). Net income: €3.50m (down 35% from 1Q 2023). Profit margin: 3.8% (down from 6.1% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany.
Reported Earnings • Apr 12Full year 2023 earnings released: EPS: €0.022 (vs €0.017 loss in FY 2022)Full year 2023 results: EPS: €0.022 (up from €0.017 loss in FY 2022). Revenue: €331.7m (up 18% from FY 2022). Net income: €9.84m (up €16.6m from FY 2022). Profit margin: 3.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany.
공시 • Apr 05Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion.Vimian Group AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.632566 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 65,302,624 Price\Range: SEK 25 Transaction Features: Regulation S; Rights Offering
Reported Earnings • Feb 16Full year 2023 earnings released: EPS: €0.022 (vs €0.017 loss in FY 2022)Full year 2023 results: EPS: €0.022 (up from €0.017 loss in FY 2022). Revenue: €331.8m (up 18% from FY 2022). Net income: €9.84m (up €16.6m from FY 2022). Profit margin: 3.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany.
Buy Or Sell Opportunity • Feb 07Now 24% undervaluedOver the last 90 days, the stock has risen 19% to €2.43. The fair value is estimated to be €3.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Meanwhile, the company became loss making.
공시 • Dec 22Vimian Group AB (publ) Announces CEO ChangesVimian Group AB (publ) appoints Patrik Eriksson Chief Executive Officer, effective 1 January 2024. Patrik Eriksson joins Vimian from Envista, a global dental company listed on NYSE, where he currently serves on the Executive Team as President of Nobel Biocare. Patrik Eriksson (56) has vast international experience from 25 years as general manager in the global medtech and life science industries. Since 2020, he is President of the dental company Nobel Biocare, part of Envista. Prior to that, he worked seven years at the global life sciences group Danaher (NYSE:DHR) as President of two of its medtech companies, KavoKerr and Ormco. He has led international organizations with more than 6,500 employees and revenues of USD 1.5 billion. He is a Swedish citizen and holds a M.Sc. in Business and Administration from the Stockholm School of Economics. Patrik Eriksson succeeds Fredrik Ullman whose departure at year-end was announced on 29 June 2023.
Reported Earnings • Nov 09Third quarter 2023 earnings released: EPS: €0.016 (vs €0.004 loss in 3Q 2022)Third quarter 2023 results: EPS: €0.016 (up from €0.004 loss in 3Q 2022). Revenue: €80.2m (up 13% from 3Q 2022). Net income: €7.43m (up €9.05m from 3Q 2022). Profit margin: 9.3% (up from net loss in 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.
공시 • Sep 26Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million.Fidelio Capital acquired a 12% stake in Vimian Group AB (publ) for approximately SEK 240 million on September 21, 2023. Fidelio Capital completed the acquisition of a 12% stake in Vimian Group AB (publ) on September 21, 2023.
Recent Insider Transactions • Sep 24Chairman of the board recently bought €20m worth of stockOn the 21st of September, Gabriel Fitzgerald bought around 10m shares on-market at roughly €1.97 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gabriel has been a buyer over the last 12 months, purchasing a net total of €20m worth in shares.
공시 • Sep 13+ 5 more updatesVimian Group AB (publ) to Report Q3, 2024 Results on Oct 24, 2024Vimian Group AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024
Reported Earnings • Aug 18Second quarter 2023 earnings released: EPS: €0.007 (vs €0.026 in 2Q 2022)Second quarter 2023 results: EPS: €0.007 (down from €0.026 in 2Q 2022). Revenue: €81.3m (up 21% from 2Q 2022). Net income: €2.99m (down 70% from 2Q 2022). Profit margin: 3.7% (down from 15% in 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
공시 • Jun 30Vimian Group AB (publ) Announces Fredrik Ullman Step Down as CEOVimian Group AB (publ) announced that CEO Fredrik Ullman, following consultation with the Board, steps down as CEO. Fredrik Ullman has been the CEO of Vimian since its inception in 2020 and the CEO of its subsidiary Indical Bioscience since 2018. The recruitment process for a new CEO will be initiated immediately with Fredrik Ullman remaining as CEO in the interim and at the latest until year-end. The recruitment process for a new CEO will be initiated immediately and Fredrik Ullman will remain as CEO in the interim.
공시 • Jun 03Vimian Group AB (Publ) Elects Robert Belkic as New Board MemberVimian Group AB (publ) at the Annual General Meeting 2 June 2023, announced Robert Belkic was newly elected, as Board members for the time until the end of the next Annual General Meeting.
Reported Earnings • May 05Full year 2022 earnings released: €0.017 loss per share (vs €0.019 profit in FY 2021)Full year 2022 results: €0.017 loss per share (down from €0.019 profit in FY 2021). Revenue: €281.3m (up 62% from FY 2021). Net loss: €6.74m (down 202% from profit in FY 2021).
Recent Insider Transactions • Mar 13Chief Executive Officer recently bought €94k worth of stockOn the 9th of March, Fredrik Ullman bought around 40k shares on-market at roughly €2.36 per share. This transaction amounted to 2.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Fredrik's only on-market trade for the last 12 months.
Reported Earnings • Mar 09Full year 2022 earnings released: €0.017 loss per share (vs €0.019 profit in FY 2021)Full year 2022 results: €0.017 loss per share (down from €0.019 profit in FY 2021). Revenue: €287.8m (up 66% from FY 2021). Net loss: €6.74m (down 202% from profit in FY 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €2.01, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 25x in the Medical Equipment industry in Europe. Total loss to shareholders of 55% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.67 per share.
Buying Opportunity • Feb 28Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €2.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 58% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings is also forecast to grow by 43% per annum over the same time period.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 20% share price gain to €2.79, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Total loss to shareholders of 59% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €2.82 per share.
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to €2.66, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 28x in the Medical Equipment industry in Europe. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €3.02 per share.
Reported Earnings • Nov 17Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €72.4m (up 75% from 3Q 2021). Net loss: €1.62m (loss widened 488% from 3Q 2021). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany.
공시 • Nov 17+ 3 more updatesVimian Group AB (publ) to Report Q2, 2023 Results on Aug 17, 2023Vimian Group AB (publ) announced that they will report Q2, 2023 results on Aug 17, 2023
Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Director Theodor Bonnier is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Valuation Update With 7 Day Price Move • Oct 29Investor sentiment improved over the past weekAfter last week's 17% share price gain to €3.00, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 67% over the past year.
공시 • Oct 25Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023Vimian Group AB (publ), Annual General Meeting, Jun 01, 2023.
Valuation Update With 7 Day Price Move • Sep 19Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €2.75, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 70% over the past year.
공시 • Sep 09Vimian Appoints Carl-Johan Ehn as General Counsel and Member of the Vimian Group Management TeamVimian appointed Carl-Johan Ehn as General Counsel and member of the Vimian Group management team as of 7 September 2022. Carl-Johan Ehn has over two decades of experience from international law in the global pharmaceutical industry at Zoetis and Pfizer, as well as from Mannheimer Swartling law firm. He joins Vimian from animal health company Zoetis where he held various leading positions over the past nine years, most recently as Chief Counsel for its international operations. The General Counsel is a new addition to the Vimian Group management team and will focus on supporting the company in the execution of commercial strategies, and ensuring high corporate governance and compliance standards. Carl-Johan Ehn joined Vimian on 15 August and was appointed member of the Vimian Group management team on 7 September.
Valuation Update With 7 Day Price Move • Sep 03Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €3.01, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 70% over the past year.
Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €68.6m (up 74% from 2Q 2021). Net income: €9.99m (up €13.1m from 2Q 2021). Profit margin: 15% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 32%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany.
공시 • Aug 03Vimian Group AB (publ) (OM:VIMIAN) acquired Heiland Gmbh.Vimian Group AB (publ) (OM:VIMIAN) acquired Heiland Gmbh on August 1, 2022. Heiland a family-owned business that has annual revenues of around €1.5 million. Vimian Group AB (publ) (OM:VIMIAN) completed the acquisition of Heiland Gmbh on August 1, 2022.
공시 • Jul 15Vimian Group AB (publ) Appoints Carl-Johan Zetterberg Boudrie as CFO and Member of Management TeamVimian Group appoints Carl-Johan Zetterberg Boudrie as new Chief Financial Officer and intends to continue to build out its finance organisation to support Vimian's growth journey. Carl-Johan assumes the position as CFO and member of the Vimian Group management team, and succeeds Henrik Halvorsen who has decided to focus on his role as CFO of Vimian's Specialty Pharma segment Nextmune. Carl-Johan Zetterberg Boudrie has extensive experience as CFO in publicly traded companies as well as from senior leadership positions within business development, M&A and management consulting at Beijer Electronics, SEB and Capgemini. The past six years, Carl-Johan held positions as CFO and subsequently CEO of the technology company Doro AB (publ) listed on Nasdaq Stockholm. Most recently, he was CEO of Careium AB (publ), a spin-off from Doro AB. Carl-Johan Zetterberg Boudrie succeeds Henrik Halvorsen who has held dual positions as CFO of Vimian and CFO of Vimian's Specialty Pharma segment Nextmune, and who now decided to focus solely on his position at Nextmune. Henrik Halvorsen will remain as Vimian's CFO until Carl-Johan Zetterberg Boudrie has assumed his position. Carl-Johan will assume the position as CFO of Vimian as soon as a successor has been appointed for his current position.
Buying Opportunity • Jun 16Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €6.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last year. Meanwhile, the company has become profitable. Revenue is forecast to grow by 73% in 2 years. Earnings is forecast to grow by 1,371% in the next 2 years.
Reported Earnings • May 06Full year 2021 earnings released: EPS: €0.019 (vs €0.18 in FY 2020)Full year 2021 results: EPS: €0.019 (down from €0.18 in FY 2020). Revenue: €173.4m (up 143% from FY 2020). Net income: €6.59m (down 88% from FY 2020). Profit margin: 3.8% (down from 74% in FY 2020). Over the next year, revenue is forecast to grow 51%, compared to a 11% growth forecast for the industry in Germany.
공시 • May 06+ 3 more updatesVimian Group AB (publ) to Report Q2, 2022 Results on Aug 11, 2022Vimian Group AB (publ) announced that they will report Q2, 2022 results on Aug 11, 2022
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theodor Bonnier is the most experienced director on the board, commencing their role in 2021. Independent Director Mikael Dolsten was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Apr 05Vimian Group AB (publ) (OM : VIMIAN) acquired VerticalVet, LLC.Vimian Group AB (publ) (OM : VIMIAN) acquired VerticalVet, LLC on April 1, 2022. Vimian Group AB (publ) (OM : VIMIAN) completed the acquisition of VerticalVet, LLC on April 1, 2022.
Reported Earnings • Mar 11Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: €0.017 (down from €0.18 in FY 2020). Revenue: €178.2m (up 150% from FY 2020). Net income: €6.59m (down 88% from FY 2020). Profit margin: 3.7% (down from 74% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 36%, compared to a 11% growth forecast for the industry in Germany.
공시 • Feb 04Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire Kahu Vet Group for €22.5 million.Vimian Group AB (publ) (OM:VIMIAN) signed an agreement to acquire Kahu Vet Group for €22.5 million on February 3, 2022. The consideration consists of upfront payment of €12.1 million and potential earnout of €10.4 million subject to financial performance over three years. The consideration of €12.1 million id financed with available funds. For the year 2021, Kahu Vet Group reported revenue of approximately €8.5 million and EBITDA of approximately €1.6 million. The transaction is expected to close on or around March 1, 2022. Selling management has committed to reinvest part of the proceeds in Vimian shares.
Reported Earnings • Dec 01Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2021 results: €0.001 loss per share. Revenue: €41.5m (flat on 3Q 2020). Net loss: €275.0k (flat on 3Q 2020). Revenue exceeded analyst estimates by 1.8%. Over the next year, revenue is forecast to grow 35%, compared to a 13% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to €7.50, the stock trades at a forward P/E ratio of 85x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €5.28 per share.
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to €7.50, the stock trades at a forward P/E ratio of 85x. Average forward P/E is 39x in the Medical Equipment industry in Germany. Simply Wall St's valuation model estimates the intrinsic value at €5.28 per share.